Results 121 to 130 of about 30,927 (236)

Ibrutinib-induced pyoderma gangrenosum

Polish Archives of Internal Medicine, 2016
Andrzej Mital, Aleksandra Wilkowska, Wioletta Barańska-Rybak, Roman Nowicki, Michał Sobjanek, Martyna Sławińska   +5 more
openaire   +3 more sources

Combination Treatment of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib and Carfilzomib in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Initial Results from a Multicenter Phase 1/2b Study

, 2015
Ajai Chari, Saurabh Chhabra, Saad Z. Usmani, Sarah Larson, Rubén Niesvizky, Jeffrey Matous, Cristina Gasparetto, Beata Holkova, Matthew A. Lunning, Jason Valent, Larry D. Anderson, Chatchada Karanes, Long Kwei, L. Chang, Thorsten Graef, Elizabeth Bilotti, Kevin T. McDonagh   +16 more
openalex   +1 more source

Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemia [PDF]

, 2017
Lian Xu, Nicholas Tsakmaklis, Guang Yang, Jiaji G. Chen, Xia Liu, Maria Demos, Amanda Kofides, Christopher J. Patterson, Kirsten Meid, Joshua Gustine, Toni Dubeau, M. Lia Palomba, Ranjana H. Advani, Jorge J. Castillo, Richard R. Furman, Zachary R. Hunter, Steven P. Treon   +16 more
openalex   +1 more source

Zanubrutinib is well tolerated and effective in patients with CLL/SLL intolerant of ibrutinib/acalabrutinib: updated results. [PDF]

Blood Adv
Shadman M, Burke JM, Cultrera J, Yimer HA, Zafar SF, Misleh J, Rao SS, Farber CM, Cohen A, Yao H, Idoine A, An Q, Flinn IW, Sharman JP.   +13 more
europepmc   +1 more source

Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL [PDF]

, 2018
Bartlett, Nancy L.
core   +1 more source

Ibrutinib therapy for lymphoplasmacytic lymphoma [PDF]

American Journal of Hematology, 2017
Margaret J. Helber, Jeremiah E. Moore, AnnaLynn M. Williams, Philip J. Meacham, Paul G. Rothberg, Clive S. Zent   +5 more
openaire   +3 more sources

Chronic oral administration of ibrutinib prevents long-term memory deficits and reduces AD pathology and neuroinflammatory responses in a mouse model of AD. [PDF]

Mol Brain
Lee HJ, Kang S, Jeong YJ, Park JH, Hwang JW, Gu CH, Jung TM, Oh S, Jang JY, Hoe HS.   +9 more
europepmc   +1 more source

Ibrutinib Enhances the Activity of Anti-CD20 Antibodies in an MCL Mouse Model: Effect of Drug at Clinically Relevant Concentrations on ADCC and ADCP

, 2015
Patrick P. Ng, Daniel Lu, Juthamas Sukbuntherng, Jutta K. Neuenburg, Danelle F. James, Betty Chang   +5 more
openalex   +1 more source

Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265 mutations [PDF]

, 2017
Patrizia Mondello, Elliott J. Brea, Elisa de Stanchina, Eneda Toska, Aaron Y. Chang, Myles Fennell, Venkatraman Seshan, Ralph Garippa, David A. Scheinberg, José Baselga, Hans‐Guido Wendel, Anas Younes   +11 more
openalex   +1 more source

In silico analysis of atrial fibrillation and hypertension mechanism of action secondary to ibrutinib/acalabrutinib in chronic lymphocytic leukemia. [PDF]

Sci Rep
Córdoba R, Bayés-Genís A, Muntañola A, Colomer D, Castro J, Leiva C, Álvarez E, Zatarain-Nicolas E.   +7 more
europepmc   +1 more source